State Street’s Minerva Neurosciences NERV Stock Holding History

State Street’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$340K	Buy	56,349 +32,330	+135%	+$185K	﹤0.01%	3750
2025 Q4	$96.6K	Buy	24,019 +7,500	+45%	+$27.8K	﹤0.01%	4051
2025 Q3	$35K	Hold	16,519	–	–	﹤0.01%	4193
2025 Q2	$28.4K	Hold	16,519	–	–	﹤0.01%	4169
2025 Q1	$28.1K	Hold	16,519	–	–	﹤0.01%	4167
2024 Q4	$36.7K	Hold	16,519	–	–	﹤0.01%	4157
2024 Q3	$44.1K	Hold	16,519	–	–	﹤0.01%	4119
2024 Q2	$52.7K	Hold	16,519	–	–	﹤0.01%	4128
2024 Q1	$42.6K	Hold	16,519	–	–	﹤0.01%	4188
2023 Q4	$102K	Hold	16,519	–	–	﹤0.01%	4055
2023 Q3	$114K	Buy	16,519 +2,800	+20%	+$25.1K	﹤0.01%	4082
2023 Q2	$125K	Hold	13,719	–	–	﹤0.01%	4159
2023 Q1	$21.9K	Hold	13,719	–	–	﹤0.01%	4677
2022 Q4	$21.8K	Hold	13,719	–	–	﹤0.01%	4719
2022 Q3	$127K	Hold	13,719	–	–	﹤0.01%	4360
2022 Q2	$45K	Sell	13,719 -1	-0%	-$4	﹤0.01%	4742
2022 Q1	$91K	Sell	13,720 -109	-0.8%	-$669	﹤0.01%	4669
2021 Q4	$89K	Hold	13,829	–	–	﹤0.01%	4602
2021 Q3	$192K	Hold	13,829	–	–	﹤0.01%	4371
2021 Q2	$257K	Sell	13,829 -57,395	-81%	-$1.24M	﹤0.01%	4121
2021 Q1	$1.66M	Sell	71,224 -3,281	-4%	-$82K	﹤0.01%	3505
2020 Q4	$1.4M	Sell	74,505 -1,819	-2%	-$45.8K	﹤0.01%	3488
2020 Q3	$1.94M	Buy	76,324 +6,682	+10%	+$181K	﹤0.01%	3208
2020 Q2	$2.01M	Buy	69,642 +5,248	+8%	+$308K	﹤0.01%	3178
2020 Q1	$3.1M	Sell	64,394 -6,869	-10%	-$414K	﹤0.01%	2856
2019 Q4	$4.05M	Sell	71,263 -5,516	-7%	-$243K	﹤0.01%	2936
2019 Q3	$4.76M	Buy	76,779 +7,610	+11%	+$431K	﹤0.01%	2809
2019 Q2	$3.12M	Buy	69,169 +6,176	+10%	+$309K	﹤0.01%	3058
2019 Q1	$3.96M	Buy	62,993 +1,022	+2%	+$61.4K	﹤0.01%	2858
2018 Q4	$3.34M	Sell	61,971 -1,439	-2%	-$105K	﹤0.01%	2904
2018 Q3	$6.37M	Buy	63,410 +3,783	+6%	+$284K	﹤0.01%	2741
2018 Q2	$3.94M	Buy	59,627 +1,237	+2%	+$75.1K	﹤0.01%	2984
2018 Q1	$2.92M	Buy	58,390 +5,052	+9%	+$243K	﹤0.01%	3023
2017 Q4	$2.58M	Buy	53,338 +4,957	+10%	+$246K	﹤0.01%	3085
2017 Q3	$2.94M	Buy	48,381 +4,558	+10%	+$261K	﹤0.01%	3037
2017 Q2	$3.1M	Buy	43,823 +6,330	+17%	+$410K	﹤0.01%	2952
2017 Q1	$2.43M	Buy	37,493 +3,100	+9%	+$241K	﹤0.01%	3016
2016 Q4	$3.23M	Buy	34,393 +3,514	+11%	+$359K	﹤0.01%	2903
2016 Q3	$3.48M	Buy	30,879 +444	+1%	+$43.1K	﹤0.01%	2756
2016 Q2	$2.48M	Buy	+30,435	New	+$1.94M	﹤0.01%	2942

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FCMV

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

SSC

Spruce Street Capital New York $416M AUM

State Street's NERV Position: Q1 2026 in Review

State Street increased its Minerva Neurosciences (NERV) stake by 135% in Q1 2026, buying an estimated $185K and bringing the position to 56,349 shares worth $340K. The position accounts for ﹤0.01% of the portfolio, ranked #3750.

State Street first reported a position in NERV in Q2 2016 and has held it in 40 quarters since. The position peaked at $6.37M in Q3 2018. 47 funds tracked by Wall St. Rank hold NERV as of Q1 2026.

State Street held 56,349 shares of Minerva Neurosciences worth $340K as of Q1 2026.
State Street bought 32,330 Minerva Neurosciences shares in Q1 2026, an estimated $185K.
Minerva Neurosciences made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3750 holding.
State Street first reported a position in Minerva Neurosciences in Q2 2016 and has held it in 40 quarters since.
State Street's Minerva Neurosciences position peaked at $6.37M in Q3 2018.
47 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2026.

Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.